{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:01:50Z","timestamp":1792504910368,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26292158"],"award-info":[{"award-number":["26292158"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vetimm.2020.110054","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T21:31:11Z","timestamp":1588023071000},"page":"110054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma"],"prefix":"10.1016","volume":"225","author":[{"given":"Noriyuki","family":"Mizutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Goto-Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Fujiwara-Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2020.110054_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.vetimm.2009.12.006","article-title":"A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs","volume":"135","author":"Abrams","year":"2010","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0010","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1939-1676.2006.tb00719.x","article-title":"Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma","volume":"20","author":"Alvarez","year":"2006","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2020.110054_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13547500701674063","article-title":"Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review","volume":"13","author":"Bien","year":"2008","journal-title":"Biomarkers"},{"key":"10.1016\/j.vetimm.2020.110054_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetimm.2019.109904","article-title":"Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum","author":"Buono","year":"2019","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1354\/vp.40-1-32","article-title":"Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes","volume":"40","author":"Burnett","year":"2003","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0030","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/00007890-199006000-00026","article-title":"Increased expression of MHC class II antigens in rejecting canine lung allografts","volume":"49","author":"Chang","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.vetimm.2020.110054_bib0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00007890-199103000-00007","article-title":"Significance of biochemical markers in early detection of canine lung allograft rejection","volume":"51","author":"Chang","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.vetimm.2020.110054_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/030089169808400107","article-title":"Analysis of interleukin-2\/interleukin-2 receptor system in advanced non-small-cell lung cancer","volume":"84","author":"De Vita","year":"1998","journal-title":"Tumori"},{"key":"10.1016\/j.vetimm.2020.110054_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00002371-200201000-00004","article-title":"Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer","volume":"25","author":"Dickerson","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.vetimm.2020.110054_bib0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.05.014","article-title":"High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma","volume":"59","author":"Dlouhy","year":"2017","journal-title":"Leukemia Res."},{"key":"10.1016\/j.vetimm.2020.110054_bib0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1748-5827.2002.tb00066.x","article-title":"Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs","volume":"43","author":"Dobson","year":"2002","journal-title":"J. Small. Anim. Pract."},{"key":"10.1016\/j.vetimm.2020.110054_bib0060","first-page":"307","article-title":"Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County","volume":"40","author":"Dorn","year":"1968","journal-title":"J. Natl. Cancer. Inst."},{"key":"10.1016\/j.vetimm.2020.110054_bib0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.vetimm.2010.11.005","article-title":"Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs","volume":"140","author":"Fellman","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0021-9975(97)80065-5","article-title":"Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin\u2019s lymphomas","volume":"117","author":"Fournel-Fleury","year":"1997","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0075","first-page":"127","article-title":"Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin\u2019s disease patients","volume":"44","author":"Frydecka","year":"1996","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.vetimm.2020.110054_bib0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1179\/1607845412Y.0000000024","article-title":"Clinical features of de novo CD25(+) diffuse large B-cell lymphoma","volume":"18","author":"Fujiwara","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.vetimm.2020.110054_bib0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0165-2427(96)05604-8","article-title":"Reactivity of antibodies directed against human antigens with surface markers on canine leukocytes","volume":"53","author":"Galkowska","year":"1996","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0090","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2020.110054_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00432-004-0600-9","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin\u2019s lymphoma: in combination with the International Prognostic Index","volume":"131","author":"Goto","year":"2005","journal-title":"J. Cancer. Res. Clin. Oncol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3960\/jslrt.53.197","volume":"53","author":"Hashimoto","year":"2013","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.vetimm.2020.110054_bib0105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jlb.64.2.135","article-title":"Soluble receptors in human disease","volume":"64","author":"Heaney","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-2427(92)90030-T","article-title":"Immunophysiological studies of interleukin-2 and canine lymphocytes","volume":"33","author":"Helfand","year":"1992","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V86.2.636.bloodjournal862636","article-title":"Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma","volume":"86","author":"Helfand","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2020.110054_bib0120","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1292\/jvms.71.769","article-title":"Aberrations of the FHIT gene and Fhit protein in canine lymphoma cell lines","volume":"71","author":"Hiraoka","year":"2009","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.vetimm.2020.110054_bib0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428190009057638","article-title":"Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin\u2019s lymphoma: a single center study in Japan","volume":"37","author":"Kono","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.vetimm.2020.110054_bib0130","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1073\/pnas.80.22.6957","article-title":"Characterization of the human receptor for T-cell growth factor","volume":"80","author":"Leonard","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.vetimm.2020.110054_bib0135","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/315669a0","article-title":"Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes","volume":"315","author":"Lowenthal","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.vetimm.2020.110054_bib0140","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2020.110054_bib0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1748-5827.2003.tb00127.x","article-title":"Owners\u2019 assessments of their dog\u2019s quality of life during palliative chemotherapy for lymphoma","volume":"44","author":"Mellanby","year":"2003","journal-title":"J. Small. Anim. Pract."},{"key":"10.1016\/j.vetimm.2020.110054_bib0150","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1292\/jvms.15-0688","article-title":"Clinical and histopathological evaluation of 16 dogs with T-zone lymphoma","volume":"78","author":"Mizutani","year":"2016","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.vetimm.2020.110054_bib0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vetimm.2016.03.018","article-title":"Evaluation of CD25-positive cells in relation to the subtypes and prognoses in various lymphoid tumours in dogs","volume":"173","author":"Mizutani","year":"2016","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-2427(97)00053-6","article-title":"Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma","volume":"59","author":"Momoi","year":"1997","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1349-7006.2009.01167.x","article-title":"Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma","volume":"100","author":"Morito","year":"2009","journal-title":"Cancer. Sci."},{"key":"10.1016\/j.vetimm.2020.110054_bib0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.2830460304","article-title":"Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms","volume":"46","author":"Nakase","year":"1994","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1034\/j.1600-0609.2001.00334.x","article-title":"A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin\u2019s lymphoma","volume":"66","author":"Niitsu","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0180","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10428190802108888","article-title":"Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy","volume":"49","author":"Oki","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.vetimm.2020.110054_bib0185","first-page":"179","article-title":"Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.vetimm.2020.110054_bib0190","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"Rubin","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0195","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.137.12.3841","article-title":"The released interleukin 2 receptor binds interleukin 2 efficiently","volume":"137","author":"Rubin","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0200","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","article-title":"The soluble interleukin-2 receptor: biology, function, and clinical application","volume":"113","author":"Rubin","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vetimm.2020.110054_bib0205","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/1097-0142(19940915)74:6<1792::AID-CNCR2820740623>3.0.CO;2-F","article-title":"Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin\u2019s lymphoma. Identification of a subset at high risk of treatment failure","volume":"74","author":"Stasi","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.vetimm.2020.110054_bib0210","first-page":"1714","article-title":"Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin\u2019s disease","volume":"142","author":"Tesch","year":"1993","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0215","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/jclinpath-2015-202934","article-title":"Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma","volume":"68","author":"Toji","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0220","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.4049\/jimmunol.136.11.4099","article-title":"A secreted form of the human interleukin 2 receptor encoded by an \u201canchor minus\u201d cDNA","volume":"136","author":"Treiger","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0225","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1080\/10428194.2018.1564824","article-title":"Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma","volume":"60","author":"Umino","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.vetimm.2020.110054_bib0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1354\/vp.43-3-241","article-title":"Canine indolent nodular lymphoma","volume":"43","author":"Valli","year":"2006","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0240","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0300985810379428","article-title":"Classification of canine malignant lymphomas according to the World Health Organization criteria","volume":"48","author":"Valli","year":"2011","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0245","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00277-001-0421-8","article-title":"Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma","volume":"81","author":"Wakao","year":"2002","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.vetimm.2008.09.004","article-title":"Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction","volume":"126","author":"Yamazaki","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2020.110054_bib0255","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2011-03-340885","article-title":"Soluble IL-2R alpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2020.110054_bib0260","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V71.4.1021.1021","article-title":"Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease","volume":"71","author":"Yasuda","year":"1988","journal-title":"Blood"}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242720300805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242720300805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:45:18Z","timestamp":1777495518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242720300805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":52,"alternative-id":["S0165242720300805"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2020.110054","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2020.110054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110054"}}